A Phase I Study of Ad-RTS-hIL-12, an Inducible Adenoviral Vector Engineered to Express hIL-12 in the Presence of the Activator Ligand Veledimex in Pediatric Brain Tumor Subjects

Trial Profile

A Phase I Study of Ad-RTS-hIL-12, an Inducible Adenoviral Vector Engineered to Express hIL-12 in the Presence of the Activator Ligand Veledimex in Pediatric Brain Tumor Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Jan 2018

At a glance

  • Drugs INXN 2001 (Primary) ; Veledimex (Primary)
  • Indications Brain cancer; Glioma
  • Focus Adverse reactions
  • Sponsors ZIOPHARM Oncology
  • Most Recent Events

    • 20 Nov 2017 According to a ZIOPHARM Oncology media release, results from this trial were presented at the 22nd Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO).
    • 06 Nov 2017 According to a ZIOPHARM Oncology media release, data will be presented at the 22nd Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO).
    • 16 Oct 2017 According to a ZIOPHARM Oncology media release, this study is being conducted at leading pediatric cancer centers across the United States, including Ann & Robert H. Lurie Childrens Hospital in Chicago, Dana-Farber Cancer Institute in Boston and the University of California, San Francisco.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top